Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.29 +1.7%	$3.00	$1.05 ▼ $3.97	$320.35M	1.89	716,057 shs	340,008 shs
AUPH Aurinia Pharmaceuticals	$8.93 -1.5%	$8.23	$5.20 ▼ $10.67	$1.23B	1.16	2.04 million shs	1.23 million shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
PAHC Phibro Animal Health	$29.18 -0.9%	$26.20	$16.16 ▼ $31.80	$1.19B	0.75	353,518 shs	199,096 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+1.25%	+3.85%	+13.31%	+141.42%	-13.39%
AUPH Aurinia Pharmaceuticals	-1.31%	0.00%	+12.67%	+10.88%	+63.13%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+4.55%
PAHC Phibro Animal Health	-1.17%	-0.98%	+18.85%	+63.65%	+56.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.2397 of 5 stars	3.5	1.0	0.0	0.0	0.0	0.8	0.6
AUPH Aurinia Pharmaceuticals	3.0017 of 5 stars	3.5	2.0	0.0	0.0	2.7	0.8	1.9
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	4.0914 of 5 stars	0.9	4.0	2.5	1.1	3.6	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	135.92% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	28.78% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-16.38% Downside

Current Analyst Ratings Breakdown

Latest ADCT, PAHC, CALT, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.60	N/A	N/A	($2.10) per share	-1.56
AUPH Aurinia Pharmaceuticals	$235.13M	5.13	$0.30 per share	29.41	$2.68 per share	3.33
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
PAHC Phibro Animal Health	$1.02B	1.16	$2.09 per share	13.93	$6.34 per share	4.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	31.89	15.95	N/A	16.11%	14.27%	9.93%	7/31/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
PAHC Phibro Animal Health	$2.42M	$0.78	37.41	13.90	0.49	2.68%	30.51%	6.89%	8/27/2025 (Estimated)

Latest ADCT, PAHC, CALT, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	N/A	N/A	N/A	$17.82 million	N/A
7/31/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.18	N/A	N/A	N/A	$64.27 million	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.64%	N/A	61.54%	N/A

Latest ADCT, PAHC, CALT, and AUPH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
PAHC Phibro Animal Health	2.67	2.91	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
AUPH Aurinia Pharmaceuticals	36.83%
CALT Calliditas Therapeutics AB (publ)	2.83%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
AUPH Aurinia Pharmaceuticals	12.20%
CALT Calliditas Therapeutics AB (publ)	2.20%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable

ADCT, PAHC, CALT, and AUPH Headlines

Recent News About These Companies

Best Growth Stocks to Buy for July 23rd

July 23 at 10:10 AM | zacks.com

Best Value Stocks to Buy for July 23rd

July 23 at 10:01 AM | zacks.com

Hussman Strategic Advisors Inc. Grows Stock Holdings in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18, 2025 | marketbeat.com

Jackson Creek Investment Advisors LLC Makes New Investment in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18, 2025 | marketbeat.com

Pzena Investment Management LLC Has $15.46 Million Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18, 2025 | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Stock Holdings Trimmed by Teacher Retirement System of Texas

July 18, 2025 | marketbeat.com

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

July 17, 2025 | zacks.com

Best Growth Stocks to Buy for July 17th

July 17, 2025 | zacks.com

3 Reasons Why Growth Investors Shouldn't Overlook Phibro (PAHC)

July 16, 2025 | zacks.com

PAHC or BSX: Which Is the Better Value Stock Right Now?

July 16, 2025 | zacks.com

Best Growth Stocks to Buy for July 15th

July 15, 2025 | zacks.com

4 Stocks Trading Near 52-Week High With More Upside Potential

July 14, 2025 | zacks.com

Phibro Animal Health (PAHC) is a Great Momentum Stock: Should ... - Nasdaq

July 12, 2025 | nasdaq.com

PAHC Phibro Animal Health Corporation - Seeking Alpha

July 12, 2025 | seekingalpha.com

Phibro Animal Health (PAHC) is a Great Momentum Stock: Should You Buy?

July 11, 2025 | msn.com

Here's Why Phibro Animal Health (PAHC) is a Strong Momentum Stock

July 11, 2025 | zacks.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Given Consensus Rating of "Reduce" by Analysts

July 11, 2025 | marketbeat.com

Phibro Animal Health (PAHC) is a Great Momentum Stock: Should You Buy?

July 10, 2025 | zacks.com

Best Growth Stocks to Buy for July 10th

July 10, 2025 | zacks.com

Invest in 4 Winning Stocks With Proven Relative Price Power

July 9, 2025 | zacks.com

JP Morgan Upgrades Phibro Animal Health (PAHC)

July 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, PAHC, CALT, and AUPH Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.28 +0.06 (+1.70%)

Closing price 03:59 PM Eastern

Extended Trading

$3.28 -0.01 (-0.30%)

As of 07:51 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.93 -0.14 (-1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$8.99 +0.06 (+0.73%)

As of 05:46 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 07/24/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Phibro Animal Health NASDAQ:PAHC

$29.18 -0.26 (-0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$29.41 +0.23 (+0.80%)

As of 06:40 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time